Noncoding RNAs in Alzheimers Disease and Related Dementias (R21 Clinical Trial Not Allowed)

Archived

National Institutes of Health

Description

The goal of this Funding Opportunity Announcement (FOA) is to stimulate research in noncoding ribonucleic acids (ncRNAs) to investigate the causality, directionality, mechanisms, and therapeutic potential of ncRNAs implicated in Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD). This FOA will support exploratory and developmental Grant (R21) applications seeking to discover functional roles of ncRNAs and underlying mechanisms involved in the pathogenesis and progression of AD/ADRD. Proposed studies should focus on functional characterization and mechanistic investigation of previously identified ncRNAs.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

NIH OER Webmaster<br/>OERWebmaster03@od.nih.gov
OERWebmaster03@od.nih.gov

Key dates & funding
  • PostedFeb 28, 2022
  • ClosesJul 15, 2022
  • CFDA93.866
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro